All Publications

Corporate spending on artificial intelligence infrastructure continues to break records in 2026, with tech giants committing hundreds of billions to AI development.

Major central banks worldwide face mounting pressure as persistent inflation and slowing growth complicate long-anticipated interest rate cut timelines.

GLP-1 receptor agonists like semaglutide and tirzepatide continue to transform obesity treatment, cardiovascular care, and healthcare systems worldwide.

Artificial intelligence is revolutionizing pharmaceutical research, compressing drug discovery timelines from decades to years and opening doors to treatments for complex diseases.

A closer look at the ingredients, additives, and ultra-processing in a bag of Cheetos, and what the science actually says about frequent consumption of foods like this.

Major corporations worldwide are dramatically accelerating AI infrastructure spending, fundamentally transforming hiring, operations, and competitive strategy across industries.

Netflix, Disney+, and emerging rivals are reshaping entertainment consumption as the streaming industry undergoes its most competitive phase yet in 2026.

Major technology companies including Microsoft, Google, and OpenAI are aggressively expanding AI agent deployments, marking a fundamental shift from chatbots to autonomous task-completing systems.

Cities and natural sites worldwide are enforcing unprecedented caps on tourist numbers as overtourism pressures reach a breaking point.

Corporate AI spending continues its historic climb in 2026, with major tech firms and enterprises doubling down on artificial intelligence infrastructure and automation.

GLP-1 receptor agonists like semaglutide continue transforming obesity treatment worldwide, with expanded access, new indications, and mounting research reshaping healthcare systems.

Major central banks including the Federal Reserve and ECB are carefully managing interest rate reductions as inflation remains stubbornly above targets in early 2026.

Devastating wildfires are ravaging multiple continents simultaneously, breaking historical records and displacing millions as climate change extends fire seasons and creates more favorable conditions for uncontrolled blazes.

Corporate spending on artificial intelligence infrastructure continues to accelerate in 2026, with tech giants committing hundreds of billions to reshape industries worldwide.

GLP-1 receptor agonists like semaglutide and tirzepatide continue transforming obesity treatment worldwide, with expanding approvals and growing evidence of broader health benefits.